D. Boral Capital reissued their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Free Report) in a research note released on Wednesday morning,Benzinga reports. The firm currently has a $12.00 price objective on the stock. BMEA has been the subject of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares […]

D. Boral Capital reissued their hold rating on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note published on Tuesday morning, MarketBeat.com reports. Several other analysts have also issued reports on PSTV. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. […]